1,720,989 research outputs found
Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
Get PDF10.1016/j.rpth.2023.102193Research and Practice in Thrombosis and Haemostasis76102193
Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study.
No full text10.1002/jha2.618EJHaem413-1
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
No full text10.1111/ejh.13783European Journal of Haematology1093205-21
Effectiveness of near-peer simulation for managing the acutely deteriorating patient among residents of an internal medicine junior residency programme
No full text10.11622/smedj.2019056SINGAPORE MEDICAL JOURNAL61134-+Singapor
Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.
No full textIptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development for paroxysmal nocturnal hemoglobinuria (PNH). In this ongoing open-label phase 2 study, PNH patients with active hemolysis were randomized to receive single-agent iptacopan twice-daily, at a dose of either 25 mg for 4 weeks followed by 100 mg for up to 2 years (cohort 1) or 50 mg for 4 weeks followed by 200 mg for up to 2 years (cohort 2). At the time of interim analysis, of 13 PNH patients enrolled, all 12 evaluable for efficacy achieved the primary endpoint of reduction in serum lactate dehydrogenase (LDH) levels by at least 60% by week 12 as compared to baseline; mean LDH levels dropped rapidly and durably, namely by 77% and 85% at week 2 and by 86% and 86% at week 12 in cohorts 1 and 2, respectively. Most patients achieved a clinically meaningful improvement in hemoglobin levels and all but one patient remained transfusion-free up to week 12. Other markers of hemolysis, including bilirubin, reticulocytes and haptoglobin, showed consistent improvements. No thromboembolic events were reported, and iptacopan was well tolerated, with no severe or serious adverse events reported up until the data cutoff. In addition to the previously reported beneficial effect of iptacopan add-on therapy to eculizumab, this study showed that iptacopan monotherapy in treatment-naïve PNH patients resulted in normalization of hemolytic markers and rapid transfusion-free improvement of hemoglobin levels in most patients. Registered at www.clinicaltrials.gov as NCT03896152
The diagnosis and treatment of venous thromboembolism in asian patients
No full text10.1186/s12959-017-0155-zTHROMBOSIS JOURNAL16
Prolonged argatroban clearance in a critically ill patient with heparin-induced thrombocytopaenia
No full text10.1136/ejhpharm-2016-001136EUROPEAN JOURNAL OF HOSPITAL PHARMACY244242-24
Atypical lymphocyte count correlates with the severity of dengue infection
No full text10.1371/journal.pone.0215061PLOS ONE14
Chief Residency Program in Singapore-10 Years On
No full text10.4300/JGME-D-18-01056Journal of graduate medical education11416-1
Chemoprophylaxis in addition to mechanical prophylaxis after total knee arthroplasty surgery does not reduce the incidence of venous thromboembolism
No full text10.1186/s12959-019-0200-1THROMBOSIS JOURNAL17
- …
